Company Active LTD

Company profile

Apoha Limited

Apoha

Materials that absorb intelligence

CRN
13344316
Founded
2021
Age
5

Overview

Legal name
APOHA LIMITED
Region
London
Registered address
NW WORKS UNITS 8 & 9
135 SALUSBURY RD
LONDON
UNITED KINGDOM
NW6 6RJ
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
25 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

11 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

02 Apr
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUxNDEyOTIxMWFkaXF6a2N4

Published 02 Apr 2026 14:48

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

16 Aug
2024

Accounts With Accounts Type Total Exemption Full

Accounts Awaiting analysis

AA | Transaction MzQzMjUxMDA1N2FkaXF6a2N4

Published 16 Aug 2024 14:41

19 Apr
2021

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2022
Funded years
2022, 2023, 2024, 2025
Age at first award
1 years

Projects

2025 Collaborative R&D Lead participant

Liquid Brain: Developing a site-deployable neuromorphic sensing and computing platform to revolutionise antibody screening

1 Jun 2025 to 31 Aug 2026

Awarded
£349,825
Total cost £499,750

Founded in 2021 by Dr Shamit Shrivastava (experimental physicist and inventor of Apoha's core platform technology; previously postdoctoral researcher at the University of Oxford) and Anshika Srivastava (skilled in operating and scaling businesses; previously Executive Director/Vice President, Goldman Sachs), Apoha is a seed-stage start-up based in London....

2025 Collaborative R&D Lead participant

Liquid Brain: Revolutionising Antibody-Target Binding and Developability Analysis with Neuromorphic Sensing and Computing

1 Jan 2025 to 30 Jun 2026

Awarded
£349,868
Total cost £499,811

For 50 years, the UK has led the world in developing monoclonal antibodies. Today, there are over 100 monoclonal antibodies approved by the US Food and Drug Administration, and the global monoclonal antibody therapeutics market is valued at USD279.8bn (Dimension Market Research). However, efforts to develop novel therapeutics remain stymied by the persist...

2024 Collaborative R&D Lead participant

Liquid Brain: Revolutionising prediction of the in vivo pharmacokinetics and biodistribution of mRNA-lipid nanoparticles

1 Dec 2024 to 31 May 2026

Awarded
£499,800
Total cost £714,000

Lipid nanoparticles (LNPs) are sub-micron-scale spherical vesicles made of ionisable lipids. They are used to safely and effectively deliver drugs including nucleic acids such as messenger RNA (mRNA) to target cells, most prominently being deployed in Pfizer-BioNTech and Moderna's mRNA-based COVID-19 vaccines. Although receiving increasing attention, LNPs...

2023 Collaborative R&D Lead participant

Apoha: Cross-cutting technology to support adoption of synthetic biology food systems

1 Sep 2023 to 28 Feb 2025

Awarded
£349,718
Total cost £499,597

Synthetic biology is poised to revolutionise future food systems, increasing sustainability, affordability, and quality for consumers, while improving resource efficiency and global food security. But, today, synthetic biology start-ups as well as FoodTech and Fast-Moving Consumer Goods innovators looking to integrate synthetic biology ingredients into no...

2022 Collaborative R&D Lead participant

Liquid Brain: Neuromorphic sensing and computing platform for high-throughput screening of antibody developability

1 Dec 2022 to 31 May 2024

Awarded
£349,607
Total cost £499,439

Drug development costs are rising and pharmaceutical R&D efficiency is falling, increasing costs for BioTech and Pharma companies, healthcare providers, and reducing affordability and accessibility for patients worldwide. 90% of drug candidates fail during clinical-stage development. Poor developability accounts for one third of clinical-stage failures of...

2022 Collaborative R&D Lead participant

Development of the world’s first universal liquid chromatography detector for pharmaceutical applications

1 Jun 2022 to 30 Nov 2023

Awarded
£349,600
Total cost £499,428

High-performance liquid chromatography (HPLC) is the most widely used analytical technique in pharmaceutical analysis, with applications spanning from detection of active pharmaceutical ingredients in drug formulations and biological fluids to quality control and assurance; for example, monitoring pharmaceutical impurities and degradation products (Siddiq...

Product types

Collaborative R&D